<i>CYP2B6</i>*<i>6</i> allele and age substantially reduce steady‐state ketamine clearance in chronic pain patients: impact on adverse effects

Abstract

The CYP2B6*6 allele is associated with a substantial decrease in steady-state ketamine plasma clearance in chronic pain patients. The decreased clearance and resultant higher plasma concentrations may be associated with a higher incidence of ketamine adverse effects.